<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18709" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bupropion</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Huecker</surname>
            <given-names>Martin R.</given-names>
          </name>
          <aff>University of Louisville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smiley</surname>
            <given-names>Abbey</given-names>
          </name>
          <aff>University of Kentucky</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Martin Huecker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abbey Smiley declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18709.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bupropion is an antidepressant medication that has received FDA approval for the treatment of depression and seasonal affective disorder and as an aid for smoking cessation. Since its approval in 1985, bupropion has been utilized off-label for various conditions, including antidepressant-induced sexual dysfunction, depression associated with bipolar disorder, obesity, and ADHD in pediatric patients. This activity reviews bupropion's clinical applications,&#x000a0;including indications, dosing, mechanism of action, adverse event profile, and toxicity. By understanding bupropion's pharmacological properties, healthcare professionals can optimize treatment regimens and reduce the risk of adverse effects, thereby improving patient outcomes. The activity also emphasizes the essential role of the interprofessional healthcare team in managing bupropion therapy, underlining the significance of collaboration and well-defined roles in patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the FDA-approved and off-label indications of bupropion.</p></list-item><list-item><p>Assess&#x000a0;the mechanism of action of bupropion.</p></list-item><list-item><p>Screen patients for contraindications and potential risks associated with bupropion therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from bupropion therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18709&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18709">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18709.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bupropion is an antidepressant that&#x000a0;can also&#x000a0;help patients stop&#x000a0;smoking.&#x000a0;This medication was first patented by Burroughs Wellcome (now part of GlaxoSmithKline) in 1974 and approved by the FDA in 1985. Under the brand name, Wellbutrin, the sustained-release (SR) formula was introduced in 1996,&#x000a0;and the extended-release (XL) formulation&#x000a0;was&#x000a0;introduced in 2003.<xref ref-type="bibr" rid="article-18709.r1">[1]</xref><xref ref-type="bibr" rid="article-18709.r2">[2]</xref>&#x000a0;In 1997, bupropion was introduced for the smoking cessation indication.<xref ref-type="bibr" rid="article-18709.r3">[3]</xref>&#x000a0;Until&#x000a0;the year 2000, the drug was sometimes referred to as amfebutamone.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult depression</p>
          </list-item>
          <list-item>
            <p>Seasonal affective disorder</p>
          </list-item>
          <list-item>
            <p>Smoking cessation&#x000a0;<xref ref-type="bibr" rid="article-18709.r4">[4]</xref><xref ref-type="bibr" rid="article-18709.r5">[5]</xref><xref ref-type="bibr" rid="article-18709.r6">[6]</xref><xref ref-type="bibr" rid="article-18709.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antidepressant-induced sexual dysfunction</p>
          </list-item>
          <list-item>
            <p>Attention-deficit/hyperactivity disorder (ADHD)</p>
          </list-item>
          <list-item>
            <p>Depression associated with bipolar disorder</p>
          </list-item>
          <list-item>
            <p>Obesity&#x000a0;<xref ref-type="bibr" rid="article-18709.r8">[8]</xref><xref ref-type="bibr" rid="article-18709.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>ADHD in pediatric patients&#x000a0;<xref ref-type="bibr" rid="article-18709.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>The American Gastroenterological Association (AGA) advises incorporating naltrexone-bupropion extended-release (ER) alongside lifestyle changes for adults with obesity instead of relying solely on lifestyle changes.<xref ref-type="bibr" rid="article-18709.r11">[11]</xref></p>
        <p>The American Thoracic Society (ATS) guidelines suggest that bupropion can be used for tobacco dependence; however, varenicline is preferred over bupropion.&#x000a0;The ATS acknowledges that future studies should assess the relative clinical effects of varenicline and bupropion in specific at-risk groups, including pregnant women, adolescents, and&#x000a0;patients with a history of treatment resistance.<xref ref-type="bibr" rid="article-18709.r12">[12]</xref></p>
        <p>The American Society of Addiction Medicine and the American Academy of Addiction Psychiatry Clinical Practice Guidelines for stimulant use disorder suggest that for patients with cocaine use disorder, clinicians may consider prescribing bupropion to support cocaine abstinence. Bupropion may also be considered for patients with co-occurring tobacco use disorder, as it can help reduce nicotine or tobacco use, and for those with co-occurring depression. For patients with amphetamine-type stimulant use disorder who use stimulants with low to moderate frequency (fewer than 18 days per month), clinicians may consider prescribing bupropion to reduce stimulant use. Additionally, bupropion may be&#x000a0;considered&#x000a0;for&#x000a0;patients with co-occurring tobacco use disorder or depressive disorders for the same reasons mentioned above.<xref ref-type="bibr" rid="article-18709.r13">[13]</xref></p>
      </sec>
      <sec id="article-18709.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Depression</bold>
</p>
        <p>Bupropion is an aminoketone antidepressant, and its mechanism of action is not fully understood.<xref ref-type="bibr" rid="article-18709.r14">[14]</xref>&#x000a0;Bupropion inhibits dopamine and norepinephrine transporters (DAT and NET), reducing the reuptake of these neurotransmitters.&#x000a0;The drug&#x000a0;reduces noradrenergic neuron activity in the locus coeruleus and increases dopaminergic activity in the nucleus accumbens. Bupropion has minimal effects on serotonin activity. The exact therapeutic mechanism in major depressive disorder is not fully defined but involves&#x000a0;the selective inhibition of norepinephrine and dopamine reuptake.<xref ref-type="bibr" rid="article-18709.r15">[15]</xref><xref ref-type="bibr" rid="article-18709.r16">[16]</xref><xref ref-type="bibr" rid="article-18709.r17">[17]</xref></p>
        <p>
<bold>Smoking Cessation</bold>
</p>
        <p>Nicotine activates cholinergic receptors in the brain and body, releasing neurotransmitters&#x000a0;such as acetylcholine, dopamine, norepinephrine, and serotonin.&#x000a0;The addictive properties of nicotine are primarily&#x000a0;the result of dopamine release in reward-related brain areas such as the ventral tegmental area and nucleus accumbens. Bupropion supports smoking cessation by targeting these circuits,&#x000a0;providing anti-craving and anti-withdrawal benefits.&#x000a0;The drug&#x000a0;inhibits the reuptake of dopamine and norepinephrine, disrupting the reward pathways linked to nicotine addiction. Additionally, bupropion may act on&#x000a0;nicotinic cholinergic receptors, improving its effectiveness in smoking cessation.<xref ref-type="bibr" rid="article-18709.r17">[17]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Bupropion is rapidly absorbed from the gastrointestinal tract. Peak serum concentrations are achieved at 2 hours for immediate release, 3 hours for sustained-release, and 5 hours for extended-release. The duration of action is 1 to 2 days. The onset of bupropion's therapeutic effect usually occurs&#x000a0;during the second week of therapy.</p>
        <p><bold>Distribution:</bold> The volume of distribution of bupropion ranges from 20&#x000a0;L/kg&#x000a0;to 47 L/kg. The plasma protein binding is approximately 85%.<xref ref-type="bibr" rid="article-18709.r18">[18]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Bupropion is metabolized to hydroxybupropion by hepatic CYP2B6.<xref ref-type="bibr" rid="article-18709.r19">[19]</xref>&#x000a0;Non-CYP metabolism follows to form erythro-hydrobupropion and threo-hydrobupropion. These metabolites&#x000a0;demonstrate a potency&#x000a0;of 20% to 50% of the parent compound. Glycinated conjugate forms of these metabolites are eliminated renally.</p>
        <p><bold>Elimination:</bold> Approximately 10% of the drug is excreted in the feces and 87% in the urine.<xref ref-type="bibr" rid="article-18709.r20">[20]</xref>&#x000a0;The distribution half-life is 3 to 4 hours. The elimination half-life of bupropion is approximately 21 hours.<xref ref-type="bibr" rid="article-18709.r18">[18]</xref></p>
      </sec>
      <sec id="article-18709.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Bupropion is administered orally; tablets are available in&#x000a0;regular&#x000a0;or extended-release formulations. Patients may take the medication with or without meals.&#x000a0;The tablets should be swallowed whole without crushing or dividing.</p>
        <p>The once-daily dosage form ranges from 75 mg to 522 mg, depending on the formulation.</p>
        <p>
<bold>Immediate-release:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available in 75 mg and 100 mg</p>
          </list-item>
        </list>
        <p><bold>Extended-release:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>12-hour tablets (hydrochloride) are available in 100 mg, 150 mg, and 200 mg</p>
          </list-item>
          <list-item>
            <p>24-hour tablets (hydrobromide) are available in 174 mg, 348 mg, and 522 mg</p>
          </list-item>
          <list-item>
            <p>24-hour tablets (hydrochloride) are available in 150 mg, 300 mg, and 450 mg</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Smoking Cessation</bold>
</p>
        <p>The&#x000a0;initial dose for smoking cessation is 150 mg once daily for 3 days.&#x000a0;This is&#x000a0;increased to 150 mg twice daily for 7 to 12 weeks. The quit attempt is typically initiated after a week of therapy.<xref ref-type="bibr" rid="article-18709.r21">[21]</xref>&#x000a0;The maximum daily dose is 450 mg.<xref ref-type="bibr" rid="article-18709.r22">[22]</xref></p>
        <p>
<bold>Seasonal Affective Disorder</bold>
</p>
        <p>The&#x000a0;initial dose is 150 mg (XL) once daily. After 7 days, the dose may be increased to 300 mg once daily in the morning. Treatment typically begins in autumn before depressive symptoms appear and continues through winter. Dosing is tapered to 150 mg, then discontinued in early spring.&#x000a0;Treatment timing and duration may be adjusted based on the patient's seasonal MDD pattern. Bupropion hydrobromide can be given orally at 174 mg daily, and after 1 week, the dosage can be increased to a&#x000a0;maintenance dose of 348 mg.</p>
        <p>
<bold>Major Depressive Disorder</bold>
</p>
        <p><bold>Immediate-release:</bold> Treatment is initiated at 100 mg every 12 hours. This is increased to 100 mg every 8 hours on&#x000a0;day 4. If therapeutic&#x000a0;goals are not met on 100mg every 8 hours&#x000a0;after several weeks, the maximum dose of 150 mg can be taken every 8 hours.</p>
        <p><bold>Sustained-release:&#x000a0;</bold>Treatment is initiated at 150 mg once daily. Clinicians can consider increasing the dose to 150 mg every 12 hours starting day 4. If therapeutic goals are unmet&#x000a0;after 4 weeks on&#x000a0;150 mg every 12 hours, the maximum dosage is 200 mg every 12 hours.</p>
        <p><bold>Extended-release:&#x000a0;</bold>Treatment is initiated at 150 mg once daily. Clinicians may increase&#x000a0;the dose to 300 mg once daily on day 4. If no clinical improvement is observed&#x000a0;after 4 weeks, the dosage may be increased to 450 mg daily.</p>
        <p>Maintenance treatment with all formulations typically requires several months or longer beyond the initial response; patients should be&#x000a0;assessed periodically to determine the need and dose for maintenance.</p>
        <p>
<bold>Dosage switching considerations</bold>
</p>
        <p>Forfivo XL can be used only after titrating initially with other bupropion medications.</p>
        <p>Patients with&#x000a0;MDD&#x000a0;switching from XL should be given the same daily dose divided equally: 3 times daily for IR, twice daily for SR, and once daily for the&#x000a0;XL formulation.</p>
        <p>When switching from hydrochloride salt formulation to hydrobromide salt (Aplenzin):</p>
        <list list-type="bullet">
          <list-item>
            <p>150 mg/day hydrochloride salt = 174 mg/day hydrobromide salt</p>
          </list-item>
          <list-item>
            <p>300 mg/day hydrochloride salt = 348 mg/day hydrobromide salt</p>
          </list-item>
          <list-item>
            <p>450 mg/day hydrochloride salt = 522 mg/day hydrobromide salt</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>According to the American Association for the Study of Liver Diseases (AASLD), antidepressants should be started at low doses in individuals with chronic liver disease (CLD). For patients receiving bupropion, the dose should be reduced by 50%, with subsequent adjustments based on the balance between therapeutic response and adverse effects.<xref ref-type="bibr" rid="article-18709.r23">[23]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;For&#x000a0;patients with renal impairment, the elimination of bupropion metabolites is reduced. Therefore, bupropion should be used cautiously, and dose adjustments are required.&#x000a0;The maximum recommended dose for patients with an eGFR of 30 to 60 mL/min is 150 mg daily.<xref ref-type="bibr" rid="article-18709.r24">[24]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Bupropion is a pregnancy class C drug. Treating pregnant women with depression requires balancing the risks of fetal medication exposure with the potential harms of untreated depression. Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are first-line treatments for these patients. Selective serotonin reuptake inhibitors (SSRIs) such as citalopram, escitalopram, and sertraline are preferred medications&#x000a0;due to their proven efficacy and safety. Bupropion is generally avoided due to limited safety data.<xref ref-type="bibr" rid="article-18709.r25">[25]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>Bupropion&#x000a0;and its metabolites are secreted into breast milk.<xref ref-type="bibr" rid="article-18709.r26">[26]</xref><xref ref-type="bibr" rid="article-18709.r27">[27]</xref><bold>&#x000a0;</bold>Maternal doses of up to 300 mg daily result in minimal bupropion levels in breast milk and are unlikely to cause adverse effects in breastfed infants. However, due to limited data and case reports suggesting potential risks, such as seizures in partially breastfed infants, bupropion should be used with caution. Alternative medications may be preferred, especially for patients with breastfeeding newborns or preterm infants, and close monitoring for symptoms such as vomiting or sedation is recommended.<xref ref-type="bibr" rid="article-18709.r28">[28]</xref></p>
        <p><bold>Pediatric patients: </bold>Bupropion is used off-label for children with attention deficit hyperactivity disorder. The usual starting dose is 3 mg/kg daily, which can be titrated to a maximum of 6 mg/kg daily.<xref ref-type="bibr" rid="article-18709.r29">[29]</xref><xref ref-type="bibr" rid="article-18709.r30">[30]</xref><xref ref-type="bibr" rid="article-18709.r31">[31]</xref> The maximum recommended dose for these patients is 150 mg. Children receiving bupropion should be monitored closely.</p>
        <p><bold>Older patients:&#x000a0;</bold>Bupropion is metabolized in the liver and excreted by the kidneys, so dose adjustments and renal function monitoring are advised, especially for older&#x000a0;adults with impaired renal function.</p>
      </sec>
      <sec id="article-18709.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Various&#x000a0;adverse effects have been reported&#x000a0;in patients receiving&#x000a0;bupropion. Many of these side effects occur in more than 10% of patients.<xref ref-type="bibr" rid="article-18709.r32">[32]</xref><xref ref-type="bibr" rid="article-18709.r33">[33]</xref><xref ref-type="bibr" rid="article-18709.r34">[34]</xref><xref ref-type="bibr" rid="article-18709.r35">[35]</xref></p>
        <p>
<bold>Cardiovascular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Tachycardia&#x000a0;<xref ref-type="bibr" rid="article-18709.r36">[36]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Respiratory</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rhinitis</p>
          </list-item>
          <list-item>
            <p>Pharyngitis&#x000a0;<xref ref-type="bibr" rid="article-18709.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Central nervous system</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Agitation</p>
          </list-item>
          <list-item>
            <p>Dizziness&#x000a0;<xref ref-type="bibr" rid="article-18709.r38">[38]</xref><xref ref-type="bibr" rid="article-18709.r39">[39]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Dermatologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pruritus</p>
          </list-item>
          <list-item>
            <p>Diaphoresis&#x000a0;<xref ref-type="bibr" rid="article-18709.r40">[40]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Endocrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Weight loss&#x000a0;<xref ref-type="bibr" rid="article-18709.r41">[41]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Dry mouth</p>
          </list-item>
          <list-item>
            <p>Nausea&#x000a0;<xref ref-type="bibr" rid="article-18709.r42">[42]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Musculoskeletal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tremor&#x000a0;<xref ref-type="bibr" rid="article-18709.r43">[43]</xref></p>
          </list-item>
          <list-item>
            <p>Arthritis&#x000a0;<xref ref-type="bibr" rid="article-18709.r44">[44]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Ophthalmologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Blurred vision&#x000a0;<xref ref-type="bibr" rid="article-18709.r43">[43]</xref></p>
          </list-item>
        </list>
        <p>The most severe adverse effects&#x000a0;include a lowered seizure threshold and worsening suicidal ideation.<xref ref-type="bibr" rid="article-18709.r39">[39]</xref></p>
        <p>Clinicians and researchers first noted epileptic seizures occurring in the 1980s; bupropion was subsequently removed from the market from 1986 through 1989. The immediate-release preparation, especially in higher doses, appears to have the highest likelihood of causing seizures.<xref ref-type="bibr" rid="article-18709.r45">[45]</xref>&#x000a0;Bupropion is one of the very few antidepressants that does not cause sexual dysfunction.<xref ref-type="bibr" rid="article-18709.r46">[46]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>CYP2B6 inducers:</bold> Bupropion is metabolized by CYP2B6, so dose adjustments may be needed with inducers like ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin.<xref ref-type="bibr" rid="article-18709.r47">[47]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>CYP2D6 substrates:</bold> Bupropion inhibits CYP2D6 (dose-dependent), potentially increasing levels of drugs such as venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline, haloperidol, risperidone, thioridazine, metoprolol, propafenone, and flecainide. A dose reduction of these drugs may be required.<xref ref-type="bibr" rid="article-18709.r48">[48]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Digoxin:</bold> Bupropion may reduce plasma levels of digoxin;&#x000a0;these levels should be monitored closely.<xref ref-type="bibr" rid="article-18709.r47">[47]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Drugs reducing seizure threshold: </bold>Use bupropion cautiously with medications that lower the seizure threshold, including antipsychotics, antidepressants, theophylline, and systemic corticosteroids.&#x000a0;Bupropion should be initiated&#x000a0;at low doses and increased gradually.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dopaminergic Drugs:</bold> Coadministration with dopaminergic drugs like levodopa and amantadine may lead to CNS toxicity.<xref ref-type="bibr" rid="article-18709.r49">[49]</xref>&#x000a0;Patients receiving these drugs should be monitored&#x000a0;for symptoms such as restlessness, agitation, tremors, ataxia, gait disturbance, vertigo, and dizziness.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Monoamine Oxidase Inhibitors (MAOIs):</bold> Using bupropion with MAOIs can increase the risk of hypertensive reactions.<xref ref-type="bibr" rid="article-18709.r50">[50]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18709.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients who are hypersensitive or allergic to bupropion or its constituents should not use the medication.</p>
        <p>Bupropion is contraindicated for patients with seizure disorder. Additionally, bupropion is also contraindicated for any other factors predisposing to seizures, ie, discontinuation of alcohol or sedatives, arteriovenous malformations, severe head injury, severe stroke, brain tumor, or other significant central nervous system disease.<xref ref-type="bibr" rid="article-18709.r51">[51]</xref></p>
        <p>Patients taking monoamine oxidase inhibitors,&#x000a0;linezolid, or methylene blue should not take bupropion. Additionally, Canadian regulations prohibit the concomitant use of thioridazine.<xref ref-type="bibr" rid="article-18709.r52">[52]</xref><xref ref-type="bibr" rid="article-18709.r53">[53]</xref></p>
        <p>Patients with a history of bulimia or anorexia nervosa should not take bupropion.</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Bupropion has an FDA-issued box warning related to suicidal thoughts and behavior in children, adolescents, and young adults. All patients who have depressive symptoms and begin any new medication should be monitored closely for suicidal signs. If symptoms worsen or overt suicidality ensues, the clinician should stop therapy.<xref ref-type="bibr" rid="article-18709.r54">[54]</xref>&#x000a0;In December 2016, researchers released a safety review; data from a large&#x000a0;clinical trial convinced the FDA that the severe mood and behavior effects of bupropion are lower than previously represented. As a result, the FDA warning for bupropion&#x000a0;for smoking cessation changed. However, the report notes that these reactions remain concerning, especially in patients with severe mood disorders or schizophrenia. This FDA report was explicitly related to the use of bupropion in smoking cessation.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>False positive amphetamine urine drug screens have been reported with the administration of bupropion; urine assays should be interpreted with caution before diagnosing substance use.<xref ref-type="bibr" rid="article-18709.r55">[55]</xref></p>
          </list-item>
          <list-item>
            <p>The doses and preparations of bupropion prescribed for the treatment of depression&#x000a0;should be prescribed&#x000a0;cautiously.<xref ref-type="bibr" rid="article-18709.r56">[56]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18709.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Bupropion does not require monitoring&#x000a0;with serum testing, and there are no firmly established therapeutic concentrations of the drug. Patients should be monitored clinically for serious adverse effects. Some patients tolerate bupropion better at lower serum concentrations; therefore, clinicians should attempt lower initial doses in all patients.</p>
        <p>Due to its metabolism by CYP enzymes, bupropion interacts with various medications. Before prescribing, the provider should determine if any existing medications interact with bupropion. Medicines&#x000a0;known to interact with bupropion include antidepressants, clopidogrel, and other drugs that lower the seizure threshold. Patients need to limit alcohol intake while on bupropion.<xref ref-type="bibr" rid="article-18709.r18">[18]</xref></p>
      </sec>
      <sec id="article-18709.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>There is extensive published data regarding&#x000a0;bupropion overdose.<xref ref-type="bibr" rid="article-18709.r57">[57]</xref>&#x000a0;The more severe exposures typically occur in an intentional overdose setting. With supportive care, unintentional overdoses usually lead to no significant effects. Accidental exposures in children are rare; a proposed 10 mg/kg safety threshold is proposed to reduce the use of healthcare resources.<xref ref-type="bibr" rid="article-18709.r58">[58]</xref>&#x000a0;</p>
        <p>Seizures&#x000a0;occur in 10% to 15% of intentional overdoses and typically occur within the first 6 hours after exposure. In overdoses of extended-release formulations, experts recommend an observation period of 24 hours due to the potential for delayed seizure onset. Though agitation and tremor often precede seizures, delayed seizures with no prior symptoms have been observed.<xref ref-type="bibr" rid="article-18709.r59">[59]</xref>&#x000a0;Other effects include hallucinations, mental status changes, agitation, and arrhythmias.<xref ref-type="bibr" rid="article-18709.r60">[60]</xref><xref ref-type="bibr" rid="article-18709.r36">[36]</xref>&#x000a0;The treating clinician should rule out&#x000a0;the presence of coingestants. Bupropion misuse is rare but has been reported.<xref ref-type="bibr" rid="article-18709.r61">[61]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Seizures should be treated with intravenous benzodiazepines. Bupropion and hydroxybupropion are highly lipid-soluble, and intravenous lipid emulsion therapy&#x000a0;can help treat bupropion overdose.<xref ref-type="bibr" rid="article-18709.r62">[62]</xref>&#x000a0;Successful use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO)&#x000a0;has been documented in patients with severe cardiotoxicity associated with bupropion overdose.<xref ref-type="bibr" rid="article-18709.r63">[63]</xref></p>
      </sec>
      <sec id="article-18709.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Physicians and nurse practitioners frequently prescribe bupropion. However, all healthcare workers who prescribe this agent must be familiar with its associated adverse effects, which occur in at least 10% of patients. The most severe adverse effects&#x000a0;include a lowered seizure threshold and the potential worsening of suicidal ideation. Clinicians should perform a mental&#x000a0;health assessment of patients at each visit and educate them on what to do if and when a seizure develops.<xref ref-type="bibr" rid="article-18709.r64">[64]</xref>&#x000a0;Pharmacists and nurses should also participate in these monitoring activities, perform medication reconciliation before drug administration, and inform the rest of the team of any concerns. This type of collaboration and communication can lead to more successful outcomes with bupropion therapy.&#x000a0;An interprofessional team approach and communication among clinicians, pharmacists, and nurses are crucial to decreasing potential adverse effects and improving patient outcomes&#x000a0;related&#x000a0;to bupropion therapy.</p>
      </sec>
      <sec id="article-18709.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18709&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18709">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18709/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18709">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18709.s11">
        <title>References</title>
        <ref id="article-18709.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Settle</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Bupropion sustained release: side effect profile.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1998</year>
            <volume>59 Suppl 4</volume>
            <fpage>32</fpage>
            <page-range>32-6</page-range>
            <pub-id pub-id-type="pmid">9554319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jefferson</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Bupropion extended-release for depressive disorders.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2008</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-22</page-range>
            <pub-id pub-id-type="pmid">18457528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkes</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bupropion.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>671</fpage>
            <page-range>671-81</page-range>
            <pub-id pub-id-type="pmid">17136226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsieh</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Stubbs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta-analysis.</article-title>
            <source>Obes Rev</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>895</fpage>
            <page-range>895-905</page-range>
            <pub-id pub-id-type="pmid">30816006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hankosky</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Dwoskin</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Talbert</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.</article-title>
            <source>AMIA Annu Symp Proc</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>1292</fpage>
            <page-range>1292-1299</page-range>
            <pub-id pub-id-type="pmid">30815171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Livingstone-Banks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hartmann-Boyce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hajek</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Relapse prevention interventions for smoking cessation.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Feb</month>
            <day>13</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD003999</fpage>
            <pub-id pub-id-type="pmid">30758045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Panchal</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2023</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>526</fpage>
            <page-range>526-533</page-range>
            <pub-id pub-id-type="pmid">37397838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clayton</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kingsberg</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Management of Hypoactive Sexual Desire Disorder.</article-title>
            <source>Sex Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>59</fpage>
            <page-range>59-74</page-range>
            <pub-id pub-id-type="pmid">29523488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verbeeck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bekkering</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Van den Noortgate</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kramers</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Oct</month>
            <day>02</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>CD009504</fpage>
            <pub-id pub-id-type="pmid">28965364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>QX</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>112</fpage>
            <page-range>112-116</page-range>
            <pub-id pub-id-type="pmid">27813651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunvald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hernaez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chandar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pickett-Blakely</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Teigen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Harindhanavudhi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davitkov</surname>
                <given-names>P</given-names>
              </name>
              <collab>AGA Clinical Guidelines Committee</collab>
            </person-group>
            <article-title>AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.</article-title>
            <source>Gastroenterology</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>163</volume>
            <issue>5</issue>
            <fpage>1198</fpage>
            <page-range>1198-1225</page-range>
            <pub-id pub-id-type="pmid">36273831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Evers-Casey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evins</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Eakin</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Fathi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fennig</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Folan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Galiatsatos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gogineni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kantrow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kathuria</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lamphere</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Neptune</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pakhale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prezant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>DPL</given-names>
              </name>
              <name>
                <surname>Toll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Upson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cruz-Lopes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fulone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pavalagantharajah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2020</year>
            <month>Jul</month>
            <day>15</day>
            <volume>202</volume>
            <issue>2</issue>
            <fpage>e5</fpage>
            <page-range>e5-e31</page-range>
            <pub-id pub-id-type="pmid">32663106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <collab>Clinical Guideline Committee (CGC) Members</collab>
            <collab>ASAM Team</collab>
            <collab>AAAP Team</collab>
            <collab>IRETA Team</collab>
            <article-title>The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.</article-title>
            <source>J Addict Med</source>
            <string-date>2024 May-Jun 01</string-date>
            <volume>18</volume>
            <issue>1S Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-56</page-range>
            <pub-id pub-id-type="pmid">38669101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paccosi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cresci</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pala</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rotella</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Parenti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Obesity Therapy: How and Why?</article-title>
            <source>Curr Med Chem</source>
            <year>2020</year>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-186</page-range>
            <pub-id pub-id-type="pmid">30678612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stahl</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Pradko</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Haight</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Modell</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rockett</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Learned-Coughlin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.</article-title>
            <source>Prim Care Companion J Clin Psychiatry</source>
            <year>2004</year>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>159</fpage>
            <page-range>159-166</page-range>
            <pub-id pub-id-type="pmid">15361919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shalabi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Glennon</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release.</article-title>
            <source>ACS Chem Neurosci</source>
            <year>2017</year>
            <month>Jun</month>
            <day>21</day>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>1397</fpage>
            <page-range>1397-1403</page-range>
            <pub-id pub-id-type="pmid">28220701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tate</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gennuso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmadzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McGregor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Girma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shekoohi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation.</article-title>
            <source>Health Psychol Res</source>
            <year>2023</year>
            <volume>11</volume>
            <fpage>81043</fpage>
            <pub-id pub-id-type="pmid">37405312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jefferson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pradko</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.</article-title>
            <source>Clin Ther</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1685</fpage>
            <page-range>1685-95</page-range>
            <pub-id pub-id-type="pmid">16368442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sayre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis.</article-title>
            <source>Pharmacotherapy</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-44</page-range>
            <pub-id pub-id-type="pmid">34752647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connarn</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Babiskin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Metabolism of bupropion by carbonyl reductases in liver and intestine.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>1019</fpage>
            <page-range>1019-27</page-range>
            <pub-id pub-id-type="pmid">25904761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Stead</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Hartmann-Boyce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants for smoking cessation.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Jan</month>
            <day>08</day>
            <volume>2014</volume>
            <issue>1</issue>
            <fpage>CD000031</fpage>
            <pub-id pub-id-type="pmid">24402784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aubin</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Tolerability and safety of sustained-release bupropion in the management of smoking cessation.</article-title>
            <source>Drugs</source>
            <year>2002</year>
            <volume>62 Suppl 2</volume>
            <fpage>45</fpage>
            <page-range>45-52</page-range>
            <pub-id pub-id-type="pmid">12109935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cotter</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Beresford</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Mental Health in Patients With Chronic Liver Disease.</article-title>
            <source>Clin Liver Dis (Hoboken)</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">36033423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagler</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zoccali</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>3736</fpage>
            <page-range>3736-45</page-range>
            <pub-id pub-id-type="pmid">22859791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacQueen</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jaworska</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lieshout</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Milev</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Ravindran</surname>
                <given-names>AV</given-names>
              </name>
              <collab>CANMAT Depression Work Group</collab>
            </person-group>
            <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.</article-title>
            <source>Can J Psychiatry</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>9</issue>
            <fpage>588</fpage>
            <page-range>588-603</page-range>
            <pub-id pub-id-type="pmid">27486149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hannaford</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bupropion and serum sickness-like reaction.</article-title>
            <source>Med J Aust</source>
            <year>2001</year>
            <month>May</month>
            <day>07</day>
            <volume>174</volume>
            <issue>9</issue>
            <fpage>479</fpage>
            <page-range>479-80</page-range>
            <pub-id pub-id-type="pmid">11386597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fokina</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rytting</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abdel-Rahman</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oncken</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hankins</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Nanovskaya</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>1832</fpage>
            <page-range>1832-1838</page-range>
            <pub-id pub-id-type="pmid">27528039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Bupropion</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Reichenbacher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ghuman</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Ghuman</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies.</article-title>
            <source>J Cent Nerv Syst Dis</source>
            <year>2013</year>
            <volume>5</volume>
            <fpage>1</fpage>
            <page-range>1-17</page-range>
            <pub-id pub-id-type="pmid">23650474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pliszka</surname>
                <given-names>S</given-names>
              </name>
              <collab>AACAP Work Group on Quality Issues</collab>
            </person-group>
            <article-title>Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>894</fpage>
            <page-range>894-921</page-range>
            <pub-id pub-id-type="pmid">17581453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conners</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Casat</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Gualtieri</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reader</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Khayrallah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ascher</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bupropion hydrochloride in attention deficit disorder with hyperactivity.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>1314</fpage>
            <page-range>1314-21</page-range>
            <pub-id pub-id-type="pmid">8885585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Gadde</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Weight Loss Medications in the Treatment of Obesity and Hypertension.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>12</day>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">30747357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pi-Sunyer</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Apovian</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McElroy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Dunayevich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Acevedo</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Greenway</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.</article-title>
            <source>Int J Obes (Lond)</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>2085</fpage>
            <page-range>2085-2094</page-range>
            <pub-id pub-id-type="pmid">30664661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Correia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Lasoff</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Minns</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>A 10-year review of single medication double-dose ingestions in the nation's largest poison control system.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-35</page-range>
            <pub-id pub-id-type="pmid">30484705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dagan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yager</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD.</article-title>
            <source>Int J Eat Disord</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>1207</fpage>
            <page-range>1207-1209</page-range>
            <pub-id pub-id-type="pmid">30230570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Druteika</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zed</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiotoxicity following bupropion overdose.</article-title>
            <source>Ann Pharmacother</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>1791</fpage>
            <page-range>1791-5</page-range>
            <pub-id pub-id-type="pmid">12398578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tackett</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Bupropion-induced angioedema.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2008</year>
            <month>Sep</month>
            <day>01</day>
            <volume>65</volume>
            <issue>17</issue>
            <fpage>1627</fpage>
            <page-range>1627-30</page-range>
            <pub-id pub-id-type="pmid">18714109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Albertson</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Metoprolol treatment of dual cocaine and bupropion cardiovascular and central nervous system toxicity.</article-title>
            <source>Clin Exp Emerg Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-88</page-range>
            <pub-id pub-id-type="pmid">29381909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Bupropion: risks and benefits.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>995</fpage>
            <page-range>995-1003</page-range>
            <pub-id pub-id-type="pmid">16255659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lineberry</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Bostwick</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Bupropion-induced erythema multiforme.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>664</fpage>
            <page-range>664-6</page-range>
            <pub-id pub-id-type="pmid">11393509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makowski</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Gwinn</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Hurren</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Naltrexone/bupropion: an investigational combination for weight loss and maintenance.</article-title>
            <source>Obes Facts</source>
            <year>2011</year>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>489</fpage>
            <page-range>489-94</page-range>
            <pub-id pub-id-type="pmid">22249001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steffens</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Doraiswamy</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>McQuoid</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Bupropion SR in the naturalistic treatment of elderly patients with major depression.</article-title>
            <source>Int J Geriatr Psychiatry</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>862</fpage>
            <page-range>862-5</page-range>
            <pub-id pub-id-type="pmid">11571765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knowles</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Shear</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Reactive metabolites and adverse drug reactions: clinical considerations.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-38</page-range>
            <pub-id pub-id-type="pmid">12721394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <article-title>Monoarthritis Induced by Bupropion Hydrochloride.</article-title>
            <source>Psychopharmacol Bull</source>
            <year>2011</year>
            <month>May</month>
            <day>15</day>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-87</page-range>
            <pub-id pub-id-type="pmid">27738357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripp</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Bupropion, a brief history of seizure risk.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2010</year>
            <season>Mar-Apr</season>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-7</page-range>
            <pub-id pub-id-type="pmid">20302998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rothmore</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant-induced sexual dysfunction.</article-title>
            <source>Med J Aust</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>212</volume>
            <issue>7</issue>
            <fpage>329</fpage>
            <page-range>329-334</page-range>
            <pub-id pub-id-type="pmid">32172535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaya</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tomaz</surname>
                <given-names>PRX</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>TMO</given-names>
              </name>
              <name>
                <surname>Nassif</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galas</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Bellini</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Moraes</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>PCL</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>PCRP</given-names>
              </name>
              <name>
                <surname>Scholz</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of bupropion and varenicline genetic markers in choosing pharmacological treatment for smoking cessation, and implications for combining drugs: A randomized controlled trial - GENTSMOKING.</article-title>
            <source>Tob Induc Dis</source>
            <year>2024</year>
            <volume>22</volume>
            <pub-id pub-id-type="pmid">38628555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hole</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arnestad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haslemo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.</article-title>
            <source>J Clin Psychopharmacol</source>
            <string-date>2021 May-Jun 01</string-date>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>281</fpage>
            <page-range>281-285</page-range>
            <pub-id pub-id-type="pmid">33905640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vismara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benatti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nicolini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Monfrini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Di Fonzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fetoni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vigan&#x000f2;</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Priori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dell'Osso</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.</article-title>
            <source>BMC Neurol</source>
            <year>2022</year>
            <month>May</month>
            <day>05</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <pub-id pub-id-type="pmid">35513785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ritter</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.</article-title>
            <source>Ann Clin Psychiatry</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-13</page-range>
            <pub-id pub-id-type="pmid">9167831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richmond</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zwar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Review of bupropion for smoking cessation.</article-title>
            <source>Drug Alcohol Rev</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-20</page-range>
            <pub-id pub-id-type="pmid">12850907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>West</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bupropion SR for smoking cessation.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>533</fpage>
            <page-range>533-40</page-range>
            <pub-id pub-id-type="pmid">12667116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.</article-title>
            <source>Can Pharm J (Ott)</source>
            <year>2016</year>
            <month>May</month>
            <volume>149</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <page-range>139-52</page-range>
            <pub-id pub-id-type="pmid">27212965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sambamoorthi</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>177</volume>
            <fpage>187</fpage>
            <page-range>187-193</page-range>
            <pub-id pub-id-type="pmid">28605678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casey</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay.</article-title>
            <source>J Med Toxicol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-8</page-range>
            <pub-id pub-id-type="pmid">21191682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saiz Ruiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez Fraile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bobes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vallejo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iglesias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iriarte</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Bupropion: efficacy and safety in the treatment of depression.</article-title>
            <source>Actas Esp Psiquiatr</source>
            <year>2011</year>
            <volume>39 Suppl 1</volume>
            <fpage>1</fpage>
            <page-range>1-25</page-range>
            <pub-id pub-id-type="pmid">22983817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Froberg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of Bupropion Overdose Compared With Selective Serotonin Reuptake Inhibitors.</article-title>
            <source>Pediatrics</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>144</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">31278211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Velez</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Keyes</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Intentional bupropion overdoses.</article-title>
            <source>J Emerg Med</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-51</page-range>
            <pub-id pub-id-type="pmid">15261357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Offerman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gosen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Padilla-Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruha</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bupropion associated seizures following acute overdose: who develops late seizures.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>1306</fpage>
            <page-range>1306-1312</page-range>
            <pub-id pub-id-type="pmid">32212940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balit</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Bupropion poisoning: a case series.</article-title>
            <source>Med J Aust</source>
            <year>2003</year>
            <month>Jan</month>
            <day>20</day>
            <volume>178</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-3</page-range>
            <pub-id pub-id-type="pmid">12526723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stassinos</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Bupropion "Abuse" Reported to US Poison Centers.</article-title>
            <source>J Addict Med</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>357</fpage>
            <page-range>357-62</page-range>
            <pub-id pub-id-type="pmid">27504927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bornstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Montrief</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Anwar Parris</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Successful Management of Adolescent Bupropion Overdose with Intravenous Lipid Emulsion Therapy.</article-title>
            <source>J Pediatr Intensive Care</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>242</fpage>
            <page-range>242-246</page-range>
            <pub-id pub-id-type="pmid">31673461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pires</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Golob</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahag&#x000fa;n</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Chebolu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ting</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Postelnicu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soetanto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Biary</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Alviar</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Harari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Confirmed Severe Bupropion Cardiotoxicity With Veno-Arterial Extracorporeal Membrane Oxygenation Initiation Prior to Cardiac Arrest.</article-title>
            <source>Cureus</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>e53768</fpage>
            <pub-id pub-id-type="pmid">38465186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18709.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>A case of recurrent seizures: Drug-drug interaction between low-dose clozapine and extended-release bupropion.</article-title>
            <source>Aust N Z J Psychiatry</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-176</page-range>
            <pub-id pub-id-type="pmid">30449126</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
